NHS England Specialised Commissioning - Thrombotic Thrombocytopenic Purpura (TTP) all ages (up to 8 Lots)

Tender description

Thrombotic Thrombocytopenic Purpura (TTP) is a serious blood disorder that results in blood clots forming in small blood vessels throughout the body. It affects the kidneys, heart and brain. If a patient is treated outside a specialist centre, mortality is 50%; in a specialist centre, it is 20%. There is also an appreciable acute morbidity, particularly in neurological disorders. The condition can be difficult to diagnose because initial presentation can be non-specific and this is a very rare disease. Rapid treatment is essential for optimal outcomes and includes plasma exchange and a range of drugs. This disease primarily affects Adults. Children are treated in paediatric haematology centres and are outside the scope of this process. Please see Section II.3 for complementary information. Lot 1: Thrombotic Thrombocytopenic Purpura (TTP) – London and the South East (Kent, Surrey, East & West Sussex) Thrombotic Thrombocytopenic Purpura (TTP) is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient’s blood is filtered and then put back into their body). The national prevalence is 330 patients in England, with an acute incidence of 150 patients. There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%. NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting interested Providers to register their interest for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015. There are patient flows to London from all over the South East. Commissioners have considered establishing one specialist provider for all of London and the South East and this is the default commissioner position. Commissioners will consider bids for the South East (Thames Valley and Hampshire and Isle of Wight areas - (Lot 2)), to facilitate patient choice and to reduce the requirement to travel for providers who meet the criteria in the service specification, in the technical questionnaire and who are willing to work within a Clinical Partnership with the successful bidder for the London and South East Lot (Lot 1). The contracting term for these services will be for a period of up to 4 years. Providers will need to register for the Provider Selection Process which is due to be published Mid-April / early May 2021. Lot 2: Thrombotic Thrombocytopenic Purpura (TTP) - South East (Thames Valley, Hampshire and the Isle of Wight) Thrombotic Thrombocytopenic Purpura (TTP) is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient’s blood is filtered and then put back into their body). The national prevalence is 330 patients in England, with an acute incidence of 150 patients. There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%. NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting interested Providers to register their interest for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015. The contracting term for these services will be for a period of up to 4 years. Providers will need to register for the Provider Selection Process which is due to be published Mid-April / early May 2021. Lot 3: Thrombotic Thrombocytopenic Purpura (TTP) - South West Thrombotic Thrombocytopenic Purpura (TTP) is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient’s blood is filtered and then put back into their body). The national prevalence is 330 patients in England, with an acute incidence of 150 patients. There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%. NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting interested Providers to register their interest for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015. The contracting term for these services will be for a period of up to 4 years. Providers will need to register for the Provider Selection Process which is due to be published Mid-April / early May 2021. Lot 4: Thrombotic Thrombocytopenic Purpura (TTP) - West Midlands Thrombotic Thrombocytopenic Purpura (TTP) is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient’s blood is filtered and then put back into their body). The national prevalence is 330 patients in England, with an acute incidence of 150 patients. There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%. NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting interested Providers to register their interest for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015. The contracting term for these services will be for a period of up to 4 years. Providers will need to register for the Provider Selection Process which is due to be published Mid-April / early May 2021. Lot 5: Thrombotic Thrombocytopenic Purpura (TTP) - East Midlands Thrombotic Thrombocytopenic Purpura (TTP) is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient’s blood is filtered and then put back into their body). The national prevalence is 330 patients in England, with an acute incidence of 150 patients. There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres centre in England where there are recognised services and where the survival rate is 80%. NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting interested Providers to register their interest for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015. The contracting term for these services will be for a period of up to 4 years. Providers will need to register for the Provider Selection Process which is due to be published Mid-April / early May 2021. Lot 6: Thrombotic Thrombocytopenic Purpura (TTP) - East of England Thrombotic Thrombocytopenic Purpura (TTP) is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient’s blood is filtered and then put back into their body). The national prevalence is 330 patients in England, with an acute incidence of 150 patients. There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%. NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting interested Providers to register their interest for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015. The contracting term for these services will be for a period of up to 4 years. Providers will need to register for the Provider Selection Process which is due to be published Mid-April / early May 2021. Lot 7: Thrombotic Thrombocytopenic Purpura (TTP) - North East Thrombotic Thrombocytopenic Purpura (TTP) is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient’s blood is filtered and then put back into their body). The national prevalence is 330 patients in England, with an acute incidence of 150 patients. There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%. NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting interested Providers to register their interest for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015. The contracting term for these services will be for a period of up to 4 years. Providers will need to register for the Provider Selection Process which is due to be published Mid-April / early May 2021. Lot 8: Thrombotic Thrombocytopenic Purpura (TTP) - Yorkshire and the Humber Thrombotic Thrombocytopenic Purpura (TTP) is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient’s blood is filtered and then put back into their body). The national prevalence is 330 patients in England, with an acute incidence of 150 patients. There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%. NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting interested Providers to register their interest for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015. The contracting term for these services will be for a period of up to 4 years. Providers will need to register for the Provider Selection Process which is due to be published Mid-April / early May 2021.